The beat-and-raise quarter supports the fundamental turnaround narrative driven by non-COVID product strength and cost discipline. The $4.3B impairment is non-cash and should not distract from operational momentum. For Q3, watch for the ~$0.10 Innovent EPS headwind and the trajectory of COVID product revenues. The CFO transition adds near-term overhang but appears orderly.
Price Chart
Executive Summary
Pfizer reported Q2 2026 adjusted EPS of $0.77 (12.9% beat vs $0.68 consensus) and revenue of $15.0B (4.5% beat vs $14.4B consensus), raised full-year 2026 revenue guidance by $500M midpoint to $60.5-$62.5B, and reaffirmed adjusted EPS guidance of $2.80-$3.00 despite absorbing a ~$0.10 impact from the Innovent biologics transaction. Strength in non-COVID products (Eliquis +19%, Padcev +23%, Lorbrena +37%) drove 18% operational growth in launched/acquired products, offsetting COVID revenue declines, while GAAP reported a net loss of $0.04 per share due to $4.3B in non-cash intangible asset impairments.
Key Financial Metrics
Key Facts
- Adjusted diluted EPS of $0.77 beat consensus of $0.68 by 13.2%
- Revenue of $15.034B rose 3% YoY (1% operational); ex-COVID, revenue grew 5% operationally
- Full-year 2026 revenue guidance raised $500M at midpoint to $60.5-$62.5B; adjusted EPS guidance reaffirmed at $2.80-$3.00
- GAAP reported a loss of $(0.04)/share due to $4.3B in non-cash intangible asset impairments (sigvotatug vedotin $3.8B, Oxbryta $525M)
- Launched & Acquired Products grew 18% operationally; Eliquis +19%, Padcev +23%, Lorbrena +37%
- COVID products Comirnaty and Paxlovid declined 34% and 95% operationally, respectively
- Announced $1.0B additional cost savings in SIA and $1.5B in manufacturing optimization savings through 2029
- Completed $1.875B exit of ViiV Healthcare stake in Q1; closed Innovent Biologics licensing deal on July 10 (recorded in Q3)
- CFO Dave Denton to step down August 15; interim CFO Cecile Guegan appointed
Financial Impact
Adjusted EPS beat by 13% and revenue beat by 4.5%; revenue guidance raised by $500M at midpoint; impairments of $4.3B (non-cash) drive GAAP loss
Risk Factors
- Sustained COVID revenue decline could pressure overall growth as non-COVID products may not fully offset in future quarters
- $4.3B asset impairments signal clinical setbacks (sigvotatug vedotin ADC, Oxbryta), raising pipeline risk
- CFO departure introduces leadership uncertainty pending permanent replacement search
- Adjusted EPS guidance unchanged despite revenue raise, reflecting dilution from Innovent deal and cost investments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000078003-26-000094 |
| Document: pfe-20260804.htm | 0000078003-26-000094 |
| Document: 0000078003-26-000094-index-headers.html | 0000078003-26-000094 |
| Document: 0000078003-26-000094-index.html | 0000078003-26-000094 |
| Document: 0000078003-26-000094.txt | 0000078003-26-000094 |
| 8-K Data (Synthetic) | 0000078003-26-000094 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | Court Ruling | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.73 (+3.46%) |
Aug 12, 2026 7w ago | Insider Buy | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.73 (+3.46%) |
Aug 12, 2026 7w ago | Insider Cluster | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.73 (+3.46%) |
Aug 6, 2026 8w ago | Insider Cluster | $26.20 $28.81 | ▲ +9.95% | ▲ +9.35% | $27.73 (+5.83%) |
Aug 5, 2026 8w ago | Insider Cluster | $26.20 $28.81 | ▲ +9.95% | ▲ +9.35% | $27.73 (+5.83%) |
Aug 4, 2026 8w ago | 8-K | $25.41 $28.55 | ▲ +12.36% | ▲ +13.60% | $27.73 (+9.12%) |
Jul 31, 2026 9w ago | Court Ruling | $25.01 $27.96 | ▼ −11.80% | ▼ −8.81% | $27.73 (−10.86%) |
Jul 24, 2026 10w ago | Court Ruling | $24.54 $28.07 | ▲ +14.38% | ▲ +10.76% | $27.73 (+12.98%) |
Jul 6, 2026 12w ago | ANALYST-DOWNGRADE | $23.72 $25.01 | ▼ −5.44% | ▼ −6.00% | $27.73 (−16.89%) |
Jun 18, 2026 15w ago | 8-K | $25.21 $25.14 | ▼ −0.28% | ▼ −0.81% | $27.73 (+9.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access